We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
+58.72%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
AUM
$1.79B
AUM Growth
+$202M
Cap. Flow
-$194M
Cap. Flow %
-10.83%
Top 10 Hldgs %
65.26%
Holding
83
New
17
Increased
15
Reduced
17
Closed
21

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$37.7M
2
CBAY
Cymabay Therapeutics
CBAY
+$25.1M
3
INCY icon
Incyte
INCY
+$16.8M
4
SYK icon
Stryker
SYK
+$16.7M
5
KURA icon
Kura Oncology
KURA
+$16.4M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$77.4M
2
DXCM icon
DexCom
DXCM
+$54.2M
3
IDXX icon
Idexx Laboratories
IDXX
+$34.1M
4
AZN icon
AstraZeneca
AZN
+$33.3M
5
ELAN icon
Elanco Animal Health
ELAN
+$27.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.32%
2 Consumer Staples 1.45%
3 Miscellaneous 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SNDX icon
76
PUT
Syndax Pharmaceuticals
SNDX
$1.62B
-450,000
Closed -$6.53M
SPY icon
77
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$808B
-50,000
Closed -$21.4M
SRPT icon
78
CALL
Sarepta Therapeutics
SRPT
$2.16B
-51,100
Closed -$6.19M
SYBX
79
DELISTED
Synlogic
SYBX
-38,331
Closed -$108K
ZNTL icon
80
Zentalis Pharmaceuticals
ZNTL
$332M
-1,211,641
Closed -$24.3M
CBAY
81
PUT
DELISTED
Cymabay Therapeutics
CBAY
-11,040
Closed -$165K

Similar funds

Sofinnova Investments's Q4 2023 Portfolio in Review

As of Q4 2023, Sofinnova Investments held 83 positions worth $1.79B, up 13% from $1.59B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Sofinnova Investments withdrew a net $194M in Q4 2023, closing 21 positions and reducing 17 holdings. Its most notable exit was Idexx Laboratories, an estimated $34.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 86% a quarter earlier, followed by Consumer Staples and Miscellaneous.

Against the trend, Sofinnova Investments opened a new position in Eli Lilly worth $37.6M.

  • Sofinnova Investments's largest Q4 2023 buy was Eli Lilly: 64,525 shares worth $37.6M.
  • Sofinnova Investments added most to Stryker in Q4 2023, an estimated $16.7M increase.
  • Sofinnova Investments's biggest Q4 2023 reduction was Natera, cutting an estimated $77.4M.
  • Sofinnova Investments fully exited Idexx Laboratories in Q4 2023, selling an estimated $34.1M.
  • Sofinnova Investments's ten largest holdings make up 65% of its $1.79B portfolio in Q4 2023.
  • Sofinnova Investments opened 17 new positions and closed 21 in Q4 2023.
  • Sofinnova Investments's portfolio value rose 13% quarter-over-quarter to $1.79B.

Based on Sofinnova Investments's 13F filing for Q4 2023, filed 13 Feb 2024.